[go: up one dir, main page]

DE69428797D1 - Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden - Google Patents

Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden

Info

Publication number
DE69428797D1
DE69428797D1 DE69428797T DE69428797T DE69428797D1 DE 69428797 D1 DE69428797 D1 DE 69428797D1 DE 69428797 T DE69428797 T DE 69428797T DE 69428797 T DE69428797 T DE 69428797T DE 69428797 D1 DE69428797 D1 DE 69428797D1
Authority
DE
Germany
Prior art keywords
benzydamine
tnf
diseases caused
treat diseases
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69428797T
Other languages
English (en)
Other versions
DE69428797T2 (de
Inventor
Valerio Cioli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Application granted granted Critical
Publication of DE69428797D1 publication Critical patent/DE69428797D1/de
Publication of DE69428797T2 publication Critical patent/DE69428797T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69428797T 1993-07-27 1994-07-14 Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden Expired - Lifetime DE69428797T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT93MI001673A IT1276040B1 (it) 1993-07-27 1993-07-27 Uso della benzidamina nel trattamento di stati patologici causati dal tnf
PCT/EP1994/002343 WO1995003799A1 (en) 1993-07-27 1994-07-14 Use of benzydamine in the treatment of pathological conditions caused by tnf

Publications (2)

Publication Number Publication Date
DE69428797D1 true DE69428797D1 (de) 2001-11-29
DE69428797T2 DE69428797T2 (de) 2002-04-18

Family

ID=11366694

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428797T Expired - Lifetime DE69428797T2 (de) 1993-07-27 1994-07-14 Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden

Country Status (25)

Country Link
US (1) US6300358B1 (de)
EP (1) EP0711163B1 (de)
JP (1) JP3587851B2 (de)
CN (1) CN1085528C (de)
AT (1) ATE207353T1 (de)
AU (1) AU692458B2 (de)
BG (1) BG62841B1 (de)
CA (1) CA2167926C (de)
CZ (1) CZ285864B6 (de)
DE (1) DE69428797T2 (de)
DK (1) DK0711163T3 (de)
ES (1) ES2163450T3 (de)
HU (1) HU226805B1 (de)
IT (1) IT1276040B1 (de)
LV (1) LV11524B (de)
NO (1) NO308195B1 (de)
NZ (1) NZ269563A (de)
PL (1) PL312741A1 (de)
PT (1) PT711163E (de)
RO (1) RO117149B1 (de)
RU (1) RU2160102C2 (de)
SI (1) SI0711163T1 (de)
SK (1) SK281895B6 (de)
WO (1) WO1995003799A1 (de)
ZA (1) ZA945431B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2201736C1 (ru) * 2001-12-24 2003-04-10 Закрытое акционерное общество "Брынцалов-А" Ушные капли бротинум
CN101199515B (zh) * 2007-12-21 2010-12-08 重庆市莱美药物技术有限公司 盐酸苄达明洗剂及其制备方法
UA103791C2 (uk) * 2009-02-10 2013-11-25 Селджин Корпорейшн Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу
AU2010270425B2 (en) * 2009-07-08 2016-07-28 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of benzydamine in the treatment of p40-dependent diseases
MD4291C1 (ro) * 2013-12-27 2015-02-28 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Preparat medicamentos pentru tratamentul otitelor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (de) * 1963-08-09
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release

Also Published As

Publication number Publication date
CZ25596A3 (en) 1996-07-17
RO117149B1 (ro) 2001-11-30
CN1130872A (zh) 1996-09-11
US6300358B1 (en) 2001-10-09
RU2160102C2 (ru) 2000-12-10
CA2167926C (en) 2004-12-21
IT1276040B1 (it) 1997-10-24
HUT73500A (en) 1996-08-28
PT711163E (pt) 2002-04-29
ITMI931673A1 (it) 1995-01-27
WO1995003799A1 (en) 1995-02-09
DE69428797T2 (de) 2002-04-18
ITMI931673A0 (it) 1993-07-27
EP0711163B1 (de) 2001-10-24
CN1085528C (zh) 2002-05-29
EP0711163A1 (de) 1996-05-15
DK0711163T3 (da) 2001-11-26
SK281895B6 (sk) 2001-09-11
CA2167926A1 (en) 1995-02-09
LV11524B (en) 1996-12-20
BG100385A (bg) 1996-09-30
ES2163450T3 (es) 2002-02-01
NO308195B1 (no) 2000-08-14
SI0711163T1 (en) 2001-12-31
ZA945431B (en) 1995-02-28
SK10596A3 (en) 1997-03-05
NZ269563A (en) 2001-03-30
BG62841B1 (bg) 2000-09-29
JP3587851B2 (ja) 2004-11-10
LV11524A (lv) 1996-10-20
NO960347D0 (no) 1996-01-26
NO960347L (no) 1996-03-07
JPH09500385A (ja) 1997-01-14
HU226805B1 (en) 2009-10-28
ATE207353T1 (de) 2001-11-15
AU692458B2 (en) 1998-06-11
CZ285864B6 (cs) 1999-11-17
AU7386194A (en) 1995-02-28
PL312741A1 (en) 1996-05-13

Similar Documents

Publication Publication Date Title
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EP0372486A3 (de) Neue Benzoesäure- und Phenylessigsäurederivate, ihre Herstellung und Verwendung als Heilmittel
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
EP1095656A3 (de) Pharmazeutische Zubereitung mit dem Cholinesterase-Hemmstoff Galanthamin
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ATE77751T1 (de) Mittel zur behandlung von knochenkrankheiten.
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
ATE191342T1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE3872881D1 (de) Arzneimittelzusammensetzung zur vorbeugung und behandlung bakterieller und viraler krankheiten.
ATE218856T1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
DE69025967D1 (de) Aryl- oder Heteroaryl-1-alkyl-pyrrol-2-carbonsäure-Derivate, zur Behandlung von durch Interleukin-1 hervorgerufenen Erkrankungen
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE3877102D1 (de) Methode fuer die behandlung von viraler gehirnentzuendung.
ATE121935T1 (de) D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren.
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition